Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Idiopathic interstitial pneumonia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    71 result(s) found for: Idiopathic interstitial pneumonia. Displaying page 2 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2015-000640-42 Sponsor Protocol Number: 1199.222 Start Date*: 2015-08-26
    Sponsor Name:Boehringer Ingelheim France
    Full Title: A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment ...
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024211-13 Sponsor Protocol Number: AC-055B202 Start Date*: 2011-05-26
    Sponsor Name:ACTELION Pharmaceuticals Ltd.
    Full Title: Long term, single-arm, open-label extension study of the MUSIC study to assess the safety and tolerability of macitentan in patients with idiopathic pulmonary fibrosis
    Medical condition: Patients with Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Prematurely Ended) SI (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000564-14 Sponsor Protocol Number: PIPF-023 Start Date*: 2013-06-18
    Sponsor Name:InterMune International AG.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenid...
    Medical condition: Patients with Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) DE (Completed) IT (Completed) AT (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-004923-63 Sponsor Protocol Number: C21 Start Date*: 2018-07-10
    Sponsor Name:Vicore Pharma AB
    Full Title: A phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of C21 in patients with Id...
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000963-42 Sponsor Protocol Number: GB29298 Start Date*: 2014-10-01
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of oral vismodegib for the treatment of idiopathic pulmonary fibrosis
    Medical condition: Idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004405-34 Sponsor Protocol Number: GS-US-231-0101 Start Date*: 2010-09-13
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmon...
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Completed) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006054-17 Sponsor Protocol Number: AC-055B201 Start Date*: Information not available in EudraCT
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis
    Medical condition: To evaluate the efficacy, safety, and tolerabilitiy of macitentan in patients with idiopathic pulmonary fibrosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) SI (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003280-11 Sponsor Protocol Number: MA29895 Start Date*: 2016-02-25
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN EXPLORATORY MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF THE SAFETY AND TOLERABILITY OF PIRFENIDONE (ESBRIET®) IN COMBINATION WITH NINTEDANIB (OFEV®) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) DK (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001091-34 Sponsor Protocol Number: 1305-0014 Start Date*: 2022-12-19
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FR (Completed) ES (Ongoing) DE (Completed) NO (Completed) EE (Completed) FI (Completed) SI (Completed) PT (Completed) SE (Completed) NL (Completed) HU (Completed) BE (Completed) IT (Completed) GR (Completed) DK (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020223-44 Sponsor Protocol Number: FinalVersion Start Date*: 2010-08-03
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Radiodiagnostik
    Full Title: (18)F-FDG PET/CT in patients with idiopathic interstitial pneumonias: correlation of tracer uptake and histological findings, and texture-based recognition of usual interstitial pneumonia
    Medical condition: Interstitial lung disease of unknown etiology
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-001253-32 Sponsor Protocol Number: HZNP-HZN-825-303 Start Date*: 2022-02-16
    Sponsor Name:Horizon Therapeutics Ireland DAC
    Full Title: A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GR (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002464-75 Sponsor Protocol Number: 534 Start Date*: 2022-12-06
    Sponsor Name:Groupe Hospitalier Paris Saint-Joseph
    Full Title: Glucocorticoids versus placebo for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a randomized controlled trial
    Medical condition: Acute exacerbation of idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005881-17 Sponsor Protocol Number: RIN-PF-303 Start Date*: 2022-08-18
    Sponsor Name:UNITED THERAPEUTICS CORPORATION
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2)
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003148-38 Sponsor Protocol Number: 1199.227 Start Date*: 2016-06-13
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) FI (Completed) HU (Completed) GB (Completed) BE (Completed) FR (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000041-14 Sponsor Protocol Number: 269050-80-06-19 Start Date*: 2020-06-19
    Sponsor Name:Norfolk and Norwich University Hospitals NHS Foundation Trust
    Full Title: The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): a randomised placebo-controlled multi-centre clinical trial
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003158-18 Sponsor Protocol Number: 203PF203 Start Date*: 2018-09-12
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis
    Medical condition: mild to moderate Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) GR (Completed) BE (Completed) ES (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003162-12 Sponsor Protocol Number: CSL312_2002 Start Date*: 2022-05-02
    Sponsor Name:CSL Behring LLC
    Full Title: A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects with Idiopathic Pulmonary Fibrosis
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) AT (Completed) PL (Completed) IT (Completed) BE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-002664-73 Sponsor Protocol Number: GALACTIC-1 Start Date*: 2020-05-25
    Sponsor Name:Galecto Biotech AB
    Full Title: GALACTIC-1- A randomized, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of GB0139...
    Medical condition: Patients with idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10067761 Exacerbation of idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) PL (Completed) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024332-42 Sponsor Protocol Number: BAY63-2521/13605 Start Date*: 2014-04-10
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmon...
    Medical condition: pulmonary hypertension associated with idiopathic interstitial pneumonias
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) BE (Completed) GB (Completed) PT (Completed) DK (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004058-32 Sponsor Protocol Number: 2014RESP02M(14-01-14) Start Date*: 2014-12-19
    Sponsor Name:Norfolk and Norwich University Hospital NHS Foundation Trust
    Full Title: The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-trimoxazole (EME-TIPAC)
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 00:16:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA